Hosted on MSN12h
Paying Docs for Prior Authorizations Among the Hot Topics at the AMA Meeting
He noted that the Improving Seniors' Timely Access to Care Act, a bill now in Congress that would more tightly regulate prior ...
manilatimes18h
Diabetes Singapore and GSK Join Forces to Spotlight Increased Risk of Viral Infections for People with Diabetes
[8] Respiratory syncytial virus (RSV) is a highly contagious and potentially serious ... GSK prioritises innovation in vaccines and specialty medicines, maximising the increasing opportunities to ...
The Pharma Letter4h
Sarepta halts development of Duchenne drug as Elevidys soars
Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...
emjreviews.com1h
BMS, Gilead and Sanofi lead Q3 market cap growth
The third quarter of 2024 brought a mix of gains and modest declines for the pharmaceutical industry’s top players, according ...
pharmaphorum18h
Sage, Biogen's zuranolone looks approvable, but will it sell?
Now, a second phase 3 trial has followed the same pattern, doing nothing to quell debate about its commercial prospects. The latest study – called CORAL and involving 440 patients with major ...